Protocol
12-004
Full Title
A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Purpose
Adenoid cystic cancers are rare tumors that affect the salivary glands and sometimes the upper airways. While surgery and radiation therapy help some patients, about 40 percent experience spread of the cancer to other parts of the body, and standard chemotherapy is typically not effective. The purpose of this study is to evaluate the safety and effectiveness of the drug axitinib in patients with adenoid cystic cancer that cannot be cured with surgery or radiation therapy or which has returned or spread despite prior treatment.
Axitinib is an oral medication which works by blocking certain proteins that play a role in the growth and progression of tumors. It is approved for treating a form of kidney cancer, but its use in adenoid cystic cancer is considered investigational.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have adenoid cystic carcinoma which cannot be cured with surgery or radiation therapy or which has returned or spread despite prior treatment.
- Patients must have evidence that the tumor is progressing.
- At least 2 weeks must have passed between completion of prior treatment (4 weeks since major surgery) and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Alan L. Ho at 646-888-4235.
Disease(s)
Head & Neck Cancer
Locations
ClinicalTrials.gov
Related Diseases
